Cargando…

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib

First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. However, all patients inev...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hirsh, Vera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488453/ https://www.ncbi.nlm.nih.gov/pubmed/26123538 http://dx.doi.org/10.1007/s40259-015-0130-9

Ejemplares similares

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
por: Nelson, Valerie, et al.
Publicado: (2013)

New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
por: Hirsh, Vera
Publicado: (2017)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
por: Morin-Ben Abdallah, Sami, et al.
Publicado: (2017)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Approach for the Design of Covalent Protein Kinase Inhibitors via Focused Deep Generative Modeling
por: Yoshimori, Atsushi, et al.
Publicado: (2022)

Assessing reversible and irreversible binding effects of kinase covalent inhibitors through ADP-Glo assays
por: Schröder, Martin, et al.
Publicado: (2021)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
por: Harvey, R Donald, et al.
Publicado: (2020)

Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
por: Köhler, Jens
Publicado: (2017)

Correction to: Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase
por: Yu, Cheng-Han, et al.
Publicado: (2018)

A Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases
por: Kathman, Stefan G., et al.
Publicado: (2014)

Next-Generation Heterocyclic Electrophiles as Small-Molecule Covalent MurA Inhibitors
por: Ábrányi-Balogh, Péter, et al.
Publicado: (2022)

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice
por: Slobbe, Paul, et al.
Publicado: (2015)

New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
por: Attili, Ilaria, et al.
Publicado: (2023)

Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer
por: Thiyagarajan, Thirumagal, et al.
Publicado: (2022)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2017)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
por: Wei, Yang, et al.
Publicado: (2021)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
por: Schuler, Martin, et al.
Publicado: (2019)

The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K
por: Mons, Elma, et al.
Publicado: (2019)

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report
por: Alshami, Jad, et al.
Publicado: (2015)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
por: Gabizon, Ronen, et al.
Publicado: (2020)

The dynamic process of covalent and non-covalent PARylation in the maintenance of genome integrity: a focus on PARP inhibitors
por: Beneyton, Adèle, et al.
Publicado: (2023)

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2023)

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
por: Kwon, Minsuk, et al.
Publicado: (2022)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
por: Park, Keunchil, et al.
Publicado: (2021)

Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib
por: Lee, Victor H. F., et al.
Publicado: (2016)

The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma
por: Shu, Wenying, et al.
Publicado: (2022)

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
por: Lu, Shun, et al.
Publicado: (2021)

Correction to Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
por: Gabizon, Ronen, et al.
Publicado: (2020)

A new solvate of afatinib, a specific inhibitor of the ErbB family of tyrosine kinases
por: Zeller, Matthias, et al.
Publicado: (2017)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Quantification of [(18)F]afatinib using PET/CT in NSCLC patients: a feasibility study
por: van de Stadt, E. A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4u021sskjglvc8q6coln4m2npe